Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered with Hexavalent Vaccine At 2, 4 and 12-15 Months of Age to Healthy Infants in Indonesia

NCT06608199 is registered in ClinicalTrials.gov with Beijing Minhai Biotechnology Co., Ltd as lead sponsor.

NCT NCT06608199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06608199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered with Hexavalent Vaccine At 2, 4 and 12-15 Months of Age to Healthy Infants in Indonesia
Lead sponsor
Beijing Minhai Biotechnology Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
November 1, 2024
Completion date
October 1, 2026
Enrollment
500 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infections, pneumococcal vaccines